This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
A novel conjugate of adalimumab and a proprietary glucocorticoid receptor modulator for patients with PMR led to longer time to flare and fewer flares and reduced the glucocorticoid dose needed.
Medscape Medical News